Apricus Bio Receives FDA Guidance on Phase 3 Study Design for RayVa" Treatment for Raynaud's Syndrome, Secondary to Scleroderma - News Press Release | PharmiWeb.com
Links shared publicly online about this topic.
- 855total visits
Apricus Bio Receives FDA Guidance on Phase 3 Study Design for RayVa" Treatment for Raynaud's Syndrome, Secondary to Scleroderma - News Press Release | PharmiWeb.com
Apricus Bio Receives FDA Guidance on Phase 3 Study Design for RayVa" Treatment for Raynaud's Syndrome, Secondary to Scleroderma - News Press Release | PharmiWeb.com
View full resource at pharmiweb.com
Tags: Neurovascular Disorder, Phase 3 Clinical Trial, FDA, Birth Control Pill, Monophasic Birth Control Pill, Apri, Desogen
Most Recently Shared on September 22, 2010 at 7:56 am By:
Press Release: Apricus Biosciences (“Apricus Bioâ€) (Nasdaq: APRI), backed by a revenue-generating CRO business and... http://bit.ly/bDmAIm
Advertisement
